Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

is open and Janssen plans to enroll 110 patients worldwide.
  • Phase Ib/II dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive non-Hodgkin's lymphoma. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP, once a safe dose is established the study will expand and report responses of this combination in patients with newly diagnosed DLBCL. This global, multi-center study, conducted by Janssen, is open and Janssen plans to enroll 33 patients.
  • Phase II study of ibrutinib in subjects with relapsed or refractory multiple myeloma (MM): This is a Phase II, multi-center, open-label trial designed trial to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in subjects with relapsed or relapsed MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone. Two further cohorts are planned to be explored; 840 mg with dexamethasone and 840 mg as a single agent. The Company anticipates an update on this study will be provided by year end 2013.
  • Phase II open-label, multicenter, single-arm study of monotherapy ibrutinib in subjects with relapsed or refractory follicular lymphoma. The primary endpoint of this study is objective response rate. Janssen plans to enroll 110 patients in this study.
  • PCYC has received Orphan Drug and Fast Track designation for ibrutinib treatment of chronic lymphocytic leukemia last year. The FDA has also granted Orphan Drug and Fast Track designation most recently to ibrutinib for the treatment of mantle cell lymphoma.  A US orphan drug designation provides the drug developer with several benefits and incentives related to the orphan drug, including a 7-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication. Fast tra
    '/>"/>

    SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
    (Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
    (Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
    (Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
    Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2
    ... 2012 Oxford BioTherapeutics (OBT) today announces that ... advisor and non-executive director.  Dr Begley, who was the Vice ... Amgen, will take on a key role in helping shape ... its pipeline of oncology antibody-based drugs into clinical development. ...
    ... Advanstar Communications, is pleased to announce the agenda for ... held April 26 - 27, 2012 at the Loews ... share their strategies for improving patient outcomes and product ... Conference highlights include: , The ...
    ... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
    Cached Biology Technology:Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 2Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 3Complete Agenda Announced for 11th Annual Patient Adherence Forum 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
    (Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
    (Date:7/28/2014)... Yale School of Medicine have pinpointed a mechanism in part ... in the blood, linking it to both type 1 and ... 28 issue of Proceedings of the National Academies of ... enzyme located in a part of the hypothalamus known ... in motion that control glucose levels in the blood," said ...
    (Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
    Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Glucose 'control switch' in the brain key to both types of diabetes 2Strategies identified to improve oral contraceptive success with obese women 2
    ... developed a clever method to purify parasitic organisms from ... proteomic studies and a deeper insight into the biology ... each year. Many infectious pathogens, like those ... have a complex life cycle alternating between free-living creature ...
    ... carbon dioxide from burning of fossil fuels might be kept below ... next few decades, say researchers. They say that less plentiful oil ... greater supplies of coal mean that it must be the main ... Biogeochemical Cycles . , ...
    ... addition to social factors when selecting a mate. In ... PLoS Genetics, scientists in China, France, and the ... be involved in mate choice in some human populations. ... Major Histocompatibility Complex (MHC), a large genomic region involved in ...
    Cached Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3
    See product name for description....
    RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
    ... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
    Porcine Serum US Origin 6 Months or Older...
    Biology Products: